Aarti Drugs Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8dlfrneh8s3k8tv46isvm367.pdf

Key Takeaways


Margin Walk: Headwinds Absorbed, Recovery Promised

Adhish Patil: "we are quite confident that once we get all these things in order, on a quarter-on-quarter basis, sequentially, our margins should steadily keep on increasing, and our ultimate target should be somewhere between 15% to 16%."

Sayakha: The Anti-Diabetic Backward-Integration Bet


Salicylic Acid: The Margin-Unlock Story


Demand Environment: Exports Strong, Domestic Waiting

Adhish Patil: "Q3 is typically a lean quarter anyways for the acute therapy. So, we hope that from Q4 onwards, there should be some slight pickup in the domestic demand. But we will come to know within two to three months."

Regulatory & Market Access Pipeline

Adhish Patil: "we are forming a product portfolio. We will consider these molecules as well, what you mentioned right now, into account and looking at our strengths and weaknesses and kind of markets, kind of client profile this certain molecule has and whether we are already dealing with those clients, based on all these factors, we will narrow down the list and start working towards that goal."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Sayakha captive utilizationAchieve 100% captive consumption for anti-diabetic seriesEnd of FY26
Sayakha ramp-upScale to fulfill entire captive requirementNext 6–12 months
Salicylic acid volumeRamp to 500 tons per monthQ4 FY26
Salicylic acid breakevenTurn EBITDA positive above ~800 tons/monthNot specified; volume-dependent
US market entryCommercialize Bicalutamide (first US product)Current quarter (Q3 FY26)
Regulated market launches (ex-US)Commercialize a few anti-diabetic products in Europe, UK, and other regulated marketsNext 6–9 months
New product revenueAdditional ₹60–70 crores top line from new launches combinedNot specified; tied to launch timelines
H2 FY26 revenue growthHigh single-digit value growthH2 FY26
FY27 revenue growth15–20% growth, conditional on salicylic acid ramp-upFY27
FY27 margin targetHit 15% EBITDA margin run rate toward end of FY27H2 FY27 or later
FY26 CAPEX₹150–200 crores investing cash flowsFY26
FY27 CAPEX~₹200 crores for Metformin expansionFY27
Debt-to-equity rangeMaintain between 0.4 and 0.7Ongoing
Tax rateNormalized rate around 25%Next three years including FY27

Key Metrics

MetricQ2 FY26
Consolidated revenue₹652.9 cr, +9% YoY
Consolidated EBITDA₹84.4 cr, +23% YoY
Consolidated EBITDA margin12.9%, +150 bps YoY
Consolidated PAT₹45.2 cr, +29% YoY
Consolidated PAT margin6.9%, +110 bps YoY
Standalone revenue₹578.9 cr, +7% YoY; 89% of consolidated revenue
Standalone EBITDA margin~13%, slightly crossed 13%
Formulation segment revenue₹82.4 cr, +26% YoY; exports contributed 68%
API segment volume growth9.33% overall; domestic flat with slight de-growth, exports +30%
CAPEX incurred during the quarter₹45.6 cr
Total debt (consolidated)₹571 cr, reduced by ₹41 cr during H1 FY26; debt-to-equity ratio 0.39
Salicylic acid plant production target300 tons/month near-term, ramping to 500 tons/month by Q4 FY26
Salicylic acid plant EBITDA breakevenExpected at ~800 tons/month
Methylamine plant capacity60 TPD, scalable to 80 TPD
Metformin capacity1,400 metric tons/month
Tax rate guidance~25% for FY26 and FY27
H2 FY26 value growth targetHigh single digit